Researchers at Biohub reported that co‑injecting a three‑amino‑acid cocktail with lipid nanoparticles (LNPs) markedly improved in vivo mRNA delivery and CRISPR editing efficiency in preclinical models. The findings, published in Science Translational Medicine and corroborated by an independent summary, present a straightforward strategy to overcome physiological barriers to LNP uptake. The teams showed that physiological metabolic conditions suppress certain amino‑acid metabolic programs, reducing LNP internalization. Supplementing the local metabolic milieu with common amino acids restored cellular receptivity, increasing payload delivery in animal models. LNPs are the nanoparticle carriers behind many mRNA therapies and vaccines; improving their in vivo performance is a core industry challenge. The approach offers a near‑term, formulation‑agnostic enhancement that could be applied to existing LNP platforms to boost therapeutic index for mRNA vaccines and gene‑editing therapies. Remaining work includes dose optimization, safety profiling, and validation across tissues and larger species.